GYRE THERAPEUTICS INC
GYRENASDAQTrading Snapshot
- Day Range
- $7.30 – $7.44
- 52-Week Range
- $5.44 – $9.42
- Volume
- $6.51B
- Avg Volume
- $8.07B
- Shares Outstanding
- 111.5M
- Next Earnings
- Nov 22, 2026
Fundamentals Snapshot
- Annual Revenue
- $117M
- Last Q Revenue
- $29M
- P/E Ratio
- -36.9
- P/S Ratio
- 6.8x
- EPS (TTM)
- $-0.17
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +0.6%
Why Investors Own GYRE
- ✓High-growth profile — revenue up +46.3% YoY with expanding US Equity exposure.
- ✓Healthy economics — 53% gross margin and 23% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
GYRE THERAPEUTICS INC
GYRE
StockOtter · stockotter.spaceAbout GYRE THERAPEUTICS INC
Gyre Therapeutics, Inc. is a pharmaceutical company dedicated to discovering, advancing, and bringing to market small-molecule drugs that target inflammation and fibrosis in various organs. The company's key anti-fibrotic medication, ETUARY (Pirfenidone), has received approval for treating idiopathic pulmonary fibrosis. Beyond this, ETUARY is also undergoing late-stage (Phase 3) clinical trials for several other conditions, including dermatomyositis and interstitial lung disease linked to systemic sclerosis, pneumoconiosis, and diabetic kidney disease. The company's pipeline further includes F351 (Hydronidone), a compound structurally related to ETUARY. F351 is currently in Phase 3 studies for chronic hepatitis B-induced liver fibrosis and is in Phase 1 trials for liver fibrosis associated with nonalcoholic associated steatohepatitis (NASH). Other programs in development feature F573, which is progressing through Phase 2 studies for acute and acute-on-chronic liver failure. Additionally, two early-stage candidates, F528 and F230, are in preclinical development, focusing on chronic obstructive pulmonary disease (COPD) and pulmonary arterial hypertension (PAH), respectively. Established in 2002, Gyre Therapeutics, Inc. is based in San Diego, California, and operates as a subsidiary of GNI USA, Inc.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Comparing Gyre Therapeutics (NASDAQ:GYRE) and Traws Pharma (NASDAQ:TRAW)
Gyre Therapeutics (NASDAQ: GYRE - Get Free Report) and Traws Pharma (NASDAQ: TRAW - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based o
Gyre Therapeutics to Participate in Upcoming September Investor Conferences
SAN DIEGO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (Gyre, Gyre Therapeutics or the Company) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company with operations in the United State
Gyre Therapeutics, Inc. (GYRE) Reports Q2 Loss, Beats Revenue Estimates
Gyre Therapeutics, Inc. (GYRE) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to earnings of $0.02 per share a year ago.
Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update
Q2 2026 revenue of $29.1 million; GAAP basic EPS: $(0.12) Full year 2026 revenue guidance of $100.5 to $111.0 million affirmed NDA for F351 (hydronidone) for CHB-induced liver fibrosis accepted by China's CDE in May 2026
Gyre Therapeutics Appoints Three New Members to its Board of Directors
SAN DIEGO, July 16, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (“Gyre”, “Gyre Therapeutics” or the “Company”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company with operations in the United